购物车
- 全部删除
- 您的购物车当前为空
Isatoribine(ANA245) free base 是一种有效的 TLR7 受体激动剂,具有抗丙型肝炎病毒感染活性,可用于研究HCV感染。
为众多的药物研发团队赋能,
让新药发现更简单!
Isatoribine(ANA245) free base 是一种有效的 TLR7 受体激动剂,具有抗丙型肝炎病毒感染活性,可用于研究HCV感染。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,780 | 现货 | |
5 mg | ¥ 4,480 | 现货 | |
10 mg | ¥ 6,380 | 现货 | |
25 mg | ¥ 9,620 | 现货 | |
50 mg | ¥ 12,900 | 现货 | |
100 mg | ¥ 17,500 | 现货 |
产品描述 | Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection. |
体内活性 | Isatoribine is a selective agonist of TLR7. In a proof-of-concept study, we found that once-daily 7-day treatment with intravenous Isatoribine 800 mg caused a significant (P = .001) reduction of plasma HCV RNA (mean, -0.76; range, -2.85 to +0.21 log(10) units) in otherwise untreated patients (n = 12) who were chronically infected with HCV. Viral load reduction occurred in patients infected with genotype 1 as well as non-genotype 1 HCV. The reduction of viral load was correlated with the induction of markers of a heightened immune antiviral state, including 2'-, 5'- oligoadenylate synthetase levels in whole blood. This treatment was well tolerated, with a low frequency of mild to moderate adverse events. In conclusion, systemic administration of the selective TLR7 agonist Isatoribine resulted in dose-dependent changes in immunologic biomarkers and a statistically significant antiviral effect with relatively few and mild side effects.[1] |
别名 | Isatoribine free base, 艾托立宾, ANA 245, Immusine, ANA-245, Isatoribine, Isatoribine monohydrate, ANA245 |
分子量 | 316.29 |
分子式 | C10H12N4O6S |
CAS No. | 122970-40-5 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 45 mg/mL (142.27 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.